Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Deferred Revenue (2018 - 2023)

Denali Therapeutics has reported Current Deferred Revenue over the past 6 years, most recently at $1.3 million for Q2 2023.

  • Quarterly Current Deferred Revenue changed N/A to $1.3 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Jun 2023, changed N/A year-over-year, with the annual reading at $290.1 million for FY2022, 939.06% up from the prior year.
  • Current Deferred Revenue was $1.3 million for Q2 2023 at Denali Therapeutics, down from $1.5 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $290.1 million in Q4 2022 and troughed at $23000.0 in Q3 2022.
  • The 5-year median for Current Deferred Revenue is $19.3 million (2019), against an average of $33.1 million.
  • The largest YoY upside for Current Deferred Revenue was 939.06% in 2022 against a maximum downside of 98.26% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $18.7 million in 2019, then grew by 6.27% to $19.9 million in 2020, then skyrocketed by 40.18% to $27.9 million in 2021, then surged by 939.06% to $290.1 million in 2022, then tumbled by 99.55% to $1.3 million in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Current Deferred Revenue are $1.3 million (Q2 2023), $1.5 million (Q1 2023), and $290.1 million (Q4 2022).